![]() Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, et al. NAC treats systemic micrometastatic disease from the beginning and reduces the tumor burden within the breast and axillary lymph nodes 2 2. Then, it was used to reduce the tumor size and achieve good cosmetic outcomes. Neoadjuvant chemotherapy (NAC) first began to be used for locally advanced, inoperable breast cancers. Of all cancers, breast cancer has the second highest death rate in women 1 1. If we can identify patients who have reached pathological complete response before neoadjuvant chemotherapy, we think we can also determine a patient-specific treatment plan at the beginning of treatment.īreast cancer Neoadjuvant chemotherapy Treatment Today, neoadjuvant chemotherapy is also used for patients with early-stage, operable breast cancer because it has been shown in many studies that reaching pathological complete response is associated with positive long-term results. The neoadjuvant chemotherapy response can be used as an early indicator of the prognosis of patients with breast cancer. With neoadjuvant chemotherapy, the size of locally advanced tumors decreases, allowing breast conserving surgery. Before neoadjuvant chemotherapy, stage T1-T2 (p=0.036), LN0-1 (p=0.026), Cerb-B2 positivity (p=0.025), and an initial nuclear grade of three (p=0.001) were found to be the factors affecting pathological complete response. For pathological complete response, T1 stage, N1 stage, NG 3, Ki-67 >20%, negative estrogen receptor, negative progesterone receptor, positive Cerb-B2, and adding trastuzumab to chemotherapy were statistically significant (p<0.05). Patients with pathological complete response had a smaller tumor diameter than the non-pathological complete response group (p=0.001). The number of pathological complete response patients was 74 (28%), and the number of non-pathological complete response patients was 188 (72%). The most common histological type was invasive ductal cancer. The median age of the patients was 51 years. METHODS:īetween 2015-2020, patients with pathological complete response who were operated on after neoadjuvant chemotherapy and sent to our clinic for radiotherapy were evaluated. The aim of this study was to examine the characteristics of patients admitted to our hospital with a diagnosis of breast cancer who reached pathological complete response after being operated following eight cycles of neoadjuvant chemotherapy. University of Health Sciences Istanbul Training and Research Hospital, Department of Radiology - Fatih, Istanbul. University of Health Sciences Istanbul Training and Research Hospital, Clinic of Pathology - Fatih, Istanbul. University of Health Sciences Istanbul Training and Research Hospital, Clinic of General Surgery - Fatih, Istanbul. University of Health Sciences Istanbul Training and Research Hospital, Department of Nuclear Medicine - Fatih, Istanbul. ![]() Rıza Umar GursuĪcıbadem Bakırköy Hospital, Department of Medical Oncology - Bakırköy, Istanbul. ![]() University of Health Sciences Istanbul Training and Research Hospital, Department of Radiation Oncology - Fatih, Istanbul.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |